



## **Ensemble Therapeutics Achieves Milestone**

*Milestone Provides Further Validation of Ensemble's Drug Discovery Platform and Approach to Develop Macrocycles and Other Small Molecule Therapies*

CAMBRIDGE, Mass., March 3, 2016 – Ensemble Therapeutics, a biotechnology company focused on discovering and developing breakthrough small molecule therapies for cancer and other serious diseases, today announced that it has achieved an early-stage research milestone in its drug discovery collaboration with Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), triggering a milestone payment to Ensemble. Under the terms of the agreement, Ensemble is applying its drug discovery platform against several Alexion targets to discover new small molecule clinical candidates. Alexion will have exclusive worldwide rights to develop and commercialize candidates arising from the collaboration.

“Achievement of this milestone provides additional validation of our proprietary drug discovery platform and our macrocycle development efforts,” said John Ripple, chief executive officer of Ensemble. “We are pleased our collaboration with Alexion continues to progress and look forward to further advancing our productive partnership.”

Ensemble is harnessing its exclusive drug discovery methodology to develop synthetic macrocycles and other novel small molecules that expand the boundaries of traditional therapeutics. With extensive expertise in cancer therapeutics, Ensemble is focused on high value targets within the immune checkpoint and ubiquitin proteasome system.

Added Mr. Ripple, “While partnering is a core component of our business strategy, we are also developing a growing internal pipeline of therapeutic candidates to treat cancer and other serious diseases, including programs that target IDO and USP9x.”

### **About Ensemble Therapeutics**

Ensemble discovers and develops small molecule therapies for cancer and other serious diseases. The company is aggressively applying its proprietary drug discovery platform to develop macrocycles and other novel small molecules against well-validated, but challenging disease targets that are not currently treated by conventional small molecules or antibodies. Ensemble's lead oncology program is focused on the immune checkpoint target IDO, which is implicated in a variety of cancers. The company also has a number of other development programs in oncology, including ubiquitin proteasome system antagonists. Ensemble was founded in 2004 by renowned Harvard Professor David R. Liu, Ph.D., and is backed by a blue-chip investor syndicate. For more information, visit [www.ensembletx.com](http://www.ensembletx.com).

### **Ensemble Media Contact:**

Michele Rozen  
Rozen Communications  
617-953-2214  
[michele@rozencommunications.com](mailto:michele@rozencommunications.com)